Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
D 3.51 3.09% 0.11
SGMO closed down 5.03 percent on Monday, January 30, 2023, on 77 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 3.09%
50 DMA Support Bullish 3.09%
50 DMA Support Bullish 1.59%
50 DMA Support Bullish 0.72%
Outside Day Range Expansion 0.72%
50 DMA Support Bullish 1.59%
Narrow Range Bar Range Contraction 1.59%
50 DMA Support Bullish 1.89%
NR7 Range Contraction 1.89%
Narrow Range Bar Range Contraction 1.89%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above 20 DMA about 3 hours ago
20 DMA Support about 3 hours ago
Rose Above 10 DMA about 3 hours ago
Up 3% about 3 hours ago
Up 2% about 3 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Sangamo BioSciences, Inc. Description

Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Emerging Technologies Molecular Biology Blastoma Glioblastoma Hemoglobin Immunodeficiency Transcription Hemophilia Huntington's Disease Transcription Factors Cell Product Hemophilia A Monogenic Transcription Factor Hemoglobinopathies Lysosomal Storage Disorder Lysosomal Storage Disorders Monogenic Diseases Deficiency Syndrome Dow Agrosciences Hoffmann La Roche

Is SGMO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.415
52 Week Low 2.721
Average Volume 1,283,966
200-Day Moving Average 4.30
50-Day Moving Average 3.40
20-Day Moving Average 3.41
10-Day Moving Average 3.46
Average True Range 0.17
RSI 49.24
ADX 16.25
+DI 21.78
-DI 18.21
Chandelier Exit (Long, 3 ATRs) 3.25
Chandelier Exit (Short, 3 ATRs) 3.23
Upper Bollinger Bands 3.69
Lower Bollinger Band 3.12
Percent B (%b) 0.49
BandWidth 16.67
MACD Line 0.03
MACD Signal Line 0.01
MACD Histogram 0.0149
Fundamentals Value
Market Cap 480.9 Million
Num Shares 141 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -3.44
Price-to-Sales 8.57
Price-to-Book 2.67
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.67
Resistance 3 (R3) 3.70 3.63 3.63
Resistance 2 (R2) 3.63 3.56 3.62 3.61
Resistance 1 (R1) 3.52 3.52 3.49 3.49 3.59
Pivot Point 3.45 3.45 3.44 3.44 3.45
Support 1 (S1) 3.34 3.38 3.31 3.31 3.21
Support 2 (S2) 3.27 3.34 3.26 3.19
Support 3 (S3) 3.16 3.27 3.18
Support 4 (S4) 3.13